Publications

Export 43 results:
Author Title Type [ Year(Asc)]
Filters: Author is Judes Poirier  [Clear All Filters]
2017
Lafaille-Magnan M-E, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS.  2017.  Odor identification as a biomarker of preclinical AD in older adults at risk.. Neurology. 89(4):327-335.
2016
Bombardier A, Beauchemin M, Gosselin N, Poirier J, De Beaumont L.  2016.  Altered Episodic Memory in Introverted Young Adults Carrying the BDNFMet Allele.. Int J Mol Sci. 17(11)
Konishi K, Bhat V, Banner H, Poirier J, Joober R, Bohbot VD.  2016.  APOE2 Is Associated with Spatial Navigational Strategies and Increased Gray Matter in the Hippocampus.. Front Hum Neurosci. 10:349.
Taschereau-Dumouchel V, Hétu S, Michon P-E, Vachon-Presseau E, Massicotte E, De Beaumont L, Fecteau S, Poirier J, Mercier C, Chagnon YC et al..  2016.  BDNF Val(66)Met Polymorphism Influences Visuomotor Associative Learning and the Sensitivity to Action Observation.. Sci Rep. 6:34907.
Gosselin N, De Beaumont L, Gagnon K, Baril A-A, Mongrain V, Blais H, Montplaisir J, Gagnon J-F, Pelleieux S, Poirier J et al..  2016.  BDNF Val66Met Polymorphism Interacts with Sleep Consolidation to Predict Ability to Create New Declarative Memories.. J Neurosci. 36(32):8390-8.
De Beaumont L, Pelleieux S, Lamarre-Théroux L, Dea D, Poirier J.  2016.  Butyrylcholinesterase K and Apolipoprotein E-ɛ4 Reduce the Age of Onset of Alzheimer's Disease, Accelerate Cognitive Decline, and Modulate Donepezil Response in Mild Cognitively Impaired Subjects.. J Alzheimers Dis. 54(3):913-922.
Lelental N, Brandner S, Kofanova O, Blennow K, Zetterberg H, Andreasson U, Engelborghs S, Mroczko B, Gabryelewicz T, Teunissen C et al..  2016.  Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics.. J Alzheimers Dis. 52(1):51-64.
Leduc V, Théroux L, Dea D, Dufour R, Poirier J.  2016.  Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.. J Mol Neurosci. 58(1):109-19.
Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.  2016.  Rationale and Structure for a New Center for Studies on Prevention of Alzheimer's Disease (StoP-AD).. J Prev Alzheimers Dis. 3(4):236-242.
Leduc V, Bourque L, Poirier J, Dufour R.  2016.  Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.. Pharmacogenet Genomics. 26(1):1-11.
Schoemaker D, Poirier J, Escobar S, Gauthier S, Pruessner J.  2016.  Selective familiarity deficits in otherwise cognitively intact aging individuals with genetic risk for Alzheimer's disease.. Alzheimers Dement (Amst). 2:132-9.
2015
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Leduc V, De Beaumont L, Théroux L, Dea D, Aisen P, Petersen RC, Dufour R, Poirier J.  2015.  HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.. Mol Psychiatry. 20(7):867-73.
2014
Poirier J, Gauthier S.  2014.  Alzheimer’s disease. The Complete Introduction.
Poirier J, Miron J, Picard C, Gormley P, Théroux L, Breitner JCS, Dea D.  2014.  Apolipoprotein E and lipid homeostasis in the etiology and treatment of sporadic Alzheimer's disease.. Neurobiol Aging. 35 Suppl 2:S3-10.
Jasmin SBélanger, Pearson V, Lalonde D, Domenger D, Théroux L, Poirier J.  2014.  Differential regulation of ABCA1 and ABCG1 gene expressions in the remodeling mouse hippocampus after entorhinal cortex lesion and liver-X receptor agonist treatment.. Brain Res. 1562:39-51.
De Schutter JW, Park J, Leung CYuen, Gormley P, Lin Y-S, Hu Z, Berghuis AM, Poirier J, Tsantrizos YS.  2014.  Multistage screening reveals chameleon ligands of the human farnesyl pyrophosphate synthase: implications to drug discovery for neurodegenerative diseases.. J Med Chem. 57(13):5764-76.
Poirier J, Miron J., Picard C..  2014.  Pharmacogenomic Approaches to the Treatment of Sporadic Alzheimer Disease using Cholinomimetic Agents. :51-63.

Pages